Compare Abbott Laboratories (ABT) vs Crowdstrike Holdings Inc (CRWD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Crowdstrike Holdings Inc — how do they compare? Abbott Laboratories trades at $111.09 (market cap $187.95B), while Crowdstrike Holdings Inc trades at $222 (market cap $225.95B). The key difference: Crowdstrike Holdings Inc is the larger of the two by market cap, and Abbott Laboratories pays a 2.32% dividend while Crowdstrike Holdings Inc pays none. Which is the better fit depends on your goals.
| ABT | CRWD | |
|---|---|---|
Market Cap | $187.95B | $225.95B |
Sector | Health | Technology |
52-Week High | $136.62 | $225.16 |
52-Week Low | $82.57 | $87.56 |
Enterprise Value | $214.96B | $222.22B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
CrowdStrike (CRWD) trades at $221.01, down 1.84% today, but maintains a strong technical uptrend with bullish moving averages and support at $219. The stock has delivered consistent earnings beats, with Q1 2026 EPS of $0.28 exceeding the $0.27 estimate. Revenue growth remains robust, climbing to $3.95 billion in 2025, though net margins are slightly negative. Recent positive news includes being named a leader in IDC's MDR/MXDR report (Business Wire, August 11, 2026) and surging cybersecurity sector interest.
Outlook is cautiously optimistic given strong revenue expansion and platform adoption, but high valuation multiples (P/E 765.02, P/S 44.07) pose risks. Analyst consensus is bullish with 76% buy ratings and a $191.74 price target, though current price exceeds this. Key risks include premium valuation sensitivity, competitive pressures, and macroeconomic impacts on tech spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →
